Evercore ISI lowered the firm’s price target on Illumina to $195 from $200 and keeps an Outperform rating on the shares after the company reported a headline revenue beat, gross margin beat and reiterated its fiscal year guidance. On the surface, “these numbers seem inline to a tad better,” but “we think the underlying paints a vastly different picture that is constructive,” the analyst tells investors. The firm sees Illumina “laying the foundations for a strong FY25, brick by brick,” the analyst added in an earnings recap note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina Reports Financial Results for First Quarter of Fiscal Year 2024
- ILMN Earnings this Week: How Will it Perform?
- Baird says FDA final LDT rule favorable for Life Sciences, Diagnostics coverage
- Illumina $1B cash outlay for Grail divestment ‘better than fears,’ says Evercore
- Illumina Gains Approval for GRAIL Divestiture Plans